Urotoday International Journal

Home > Why Publish with UIJ

About UroToday International Journal (UIJ)

E-mail
Editorial Letter Editorial Team About UroToday International Journal (UIJ)

UroToday International Journal is a peer-reviewed, open-access journal that publishes many types of articles about clinical urology and basic research in urology.

Rapid publication
The journal editors and editorial board strive to provide rapid publication of important manuscripts to a worldwide audience without the constraints of expensive, hard to access, traditional bound journals. UroToday International Journal is designed to improve publication access of both well-established authors in urology and burgeoning writers, by allowing all interested scientists to participate free of cost.

No Cost
There is no charge to register, submit, or publish an article in the UroToday International Journal. Additionally, there are no charges for color figures.

Readership
Readership consists of members of the worldwide urology community from more than 120 countries.

Copyright
Authors maintain all copyrights to their published articles.

The journal editors welcome submission of:

  • Original Studies
  • Mini Reports
  • Case Reports
  • Reviews
  • Rapid Communications
  • Letters to the Editor
  • Commentaries


Additional Information:

  • All articles are indexed by Scopus (Elsevier B.V.), Excerpta Medica Database (Embase; Elsevier B.V.), and Google, which offers additional massive world-wide-web exposure.
  • Authors and readers who have questions regarding submission of manuscripts or viewing of published articles with UroToday International Journal should contact the editors at editors@urotoday.com


Topics of interest include but are not limited to:

  • Urologic Oncology (Cancer)
  • Urologic Reconstruction
  • Urologic Trauma
  • Infertility
  • Andrology
  • Impotence
  • Pediatric Urology
  • Neurourology
  • Female Urology
  • Incontinence
  • Urologic outcomes
  • Epidemiology
  • Urologic Laparoscopy/Robotics
  • Urologic Transplant
  • Infectious Diseases in Urology
  • Transexual surgery
  • Adrenal gland
  • Emergencies in Urology


UroToday International Journal publishes bimonthly issues and supplements. Supplements are specifically targeted at topics of heightened interest. All manuscripts for both regular issues and supplements go through a peer review process.

case diagnosis

Participate Now
CME - Frequently Asked Questions in Improving Detection and Initial Treatment of Bladder Cancer


Presented by the Warren Alpert Medical School of Brown University, Office of Continuing Medical Education.

Target Audience

This activity is designed for urologists and other healthcare professionals interested in or involved with the management of bladder cancer.

Educational Objectives

Upon completion of this activity, participants should be able to:

  1. Discuss the epidemiology of bladder cancer including prevalence, mortality, and risk factors
  2. Describe the economic impact of bladder cancer and how improved techniques for initial detection and at the time of transurethral resection of bladder tumor (TURBT) may decrease the economic burden
  3. Compare and contrast new urine biomarkers when compared to urine cytology
  4. Discuss the role of photodynamic diagnosis using hexaminolevulinate-guided fluorescence cystoscopy in detecting carcinoma in situ and residual disease at the time of TURBT compared to traditional white-light cystoscopy (WLC)
  5. Optimize use of intravesical therapy after TURBT to prevent recurrence of bladder...
    Take CME
CME - Frequently Asked Questions in the Management of Castrate-Resistant Prostate Cancer (CRPC)

An Expert Panel Interview

Educational Objectives

At the conclusion of this activity, participants should be able to:

  • Identify patients with castrate-resistant prostate cancer (CRPC)

  • Review current and future modalities available for the treatment of CRPC.

  • Discuss therapeutic strategies that may mitigate skeletal adverse events associated with metastatic prostate cancer and its treatment.

  • Program Release: April 1, 2011

  • Program Expiration: April 30, 2012

  • Estimated time to complete: 60 minutes

  • There are no prerequisites for participation.

  • 1 AMA PRA Category 1 Credit™

  • Educational grant provided by Amgen Inc and Dendreon Corporation.

Take CME
mobile news
Visit our mobile news channel today and get the latest Urological reviews, conference coverage, surgical techniques, clinical updates and more!